

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CA125 all lab mean:</b>							<b>CA125 TOSOH AIA (TOM/TO1) mean:</b>						
mean	17.7	30.8	52.7	36.9	28.5		mean	18.8	32.0	56.0	39.7	28.7	
SD	2.6	4.3	7.2	5.0	3.9		SD	0.3	1.0	1.0	0.9	1.8	
%CV	14.9%	13.8%	13.7%	13.5%	13.6%		%CV	1.6%	3.0%	1.8%	2.2%	6.3%	
N	117	118	118	118	118		N	4	4	4	4	4	
mean+3SD	25.7	43.6	74.3	51.9	40.1		mean+3SD	19.7	34.9	58.9	42.3	34.1	
mean-3SD	9.8	18.0	31.1	22.0	16.9		mean-3SD	17.8	29.1	53.0	37.1	23.3	
mean/all kit median	1.01	1.00	1.01	1.02	1.02	1.01	kit median	18.7	32.4	55.9	39.6	28.8	
							mean/all kit median	1.07	1.04	1.08	1.09	1.03	1.06
<b>CA125 TOSOH ST A1A-pack (TOM/TO2) mean:</b>							<b>CA125 DPC Immulite 2000 (DPD/DP5) mean:</b>						
mean	21.9	37.4	63.8	43.9	33.8		mean	17.5	30.8	53.1	36.5	27.9	
SD	1.3	2.1	3.5	2.3	1.3		SD	1.2	1.4	3.2	1.9	1.3	
%CV	6.0%	5.6%	5.4%	5.1%	3.8%		%CV	7.1%	4.6%	6.1%	5.3%	4.8%	
N	3	3	3	3	3		N	25	26	26	26	26	
mean+3SD	25.8	43.7	74.2	50.6	37.6		mean+3SD	21.2	35.1	62.8	42.3	31.9	
mean-3SD	18.0	31.1	53.4	37.1	30.0		mean-3SD	13.8	26.6	43.4	30.8	23.9	
kit median	21.7	36.5	65.5	43.9	34.1		kit median	17.5	31.0	53.7	37.0	27.8	
mean/all kit median	1.25	1.22	1.23	1.21	1.21	1.22	mean/all kit median	1.00	1.00	1.02	1.01	1.00	1.01
<b>CA125 Abbott Asxym (ABB/AB1) mean:</b>							<b>CA125 Bayer ADVIA-Centaur (COB/BA1) mean:</b>						
mean	20.3	36.5	62.4	44.5	35.1		mean	17.9	30.2	51.3	35.6	28.1	
SD	3.1	4.1	5.2	4.3	3.6		SD	1.1	1.5	2.5	2.2	1.1	
%CV	15.4%	11.2%	8.3%	9.7%	10.3%		%CV	6.3%	5.0%	5.0%	6.2%	4.1%	
N	15	15	15	15	15		N	29	29	29	29	29	
mean+3SD	29.7	48.7	78.0	57.5	46.0		mean+3SD	21.3	34.7	58.9	42.2	31.5	
mean-3SD	11.0	24.3	46.9	31.5	24.3		mean-3SD	14.6	25.6	43.6	29.0	24.7	
kit median	19.6	37.3	62.7	43.2	34.8		kit median	18.0	30.3	52.0	36.0	28.1	
mean/all kit median	1.16	1.19	1.20	1.23	1.26	1.21	mean/all kit median	1.02	0.98	0.99	0.98	1.01	1.00
<b>CA125 Beckman Unicel &amp; Access (BCU &amp; BCX/BC1) mean:</b>							<b>CA125 DPC Immulite 1000 (DPB/DP5) mean:</b>						
mean	19.9	35.3	59.6	41.5	30.9		mean	17.1	30.8	52.0	35.7	26.7	
SD	1.6	2.0	5.3	3.3	1.5		SD	1.7	2.4	2.7	0.9	1.7	
%CV	7.9%	5.7%	8.8%	7.9%	5.0%		%CV	9.9%	7.7%	5.3%	2.7%	6.3%	
N	8	8	8	8	8		N	4	4	4	4	4	
mean+3SD	24.6	41.3	75.4	51.3	35.5		mean+3SD	22.1	37.9	60.2	38.5	31.8	
mean-3SD	15.1	29.3	43.8	31.7	26.2		mean-3SD	12.0	23.7	43.8	32.9	21.7	
kit median	19.8	35.4	60.1	41.6	31.2		kit median	17.1	29.8	52.1	35.6	26.6	
mean/all kit median	1.13	1.15	1.15	1.14	1.11	1.14	mean/all kit median	0.97	1.00	1.00	0.98	0.96	0.98

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CA125 DPC Immulite 2500 (DPF/DP5) mean:</b>							<b>CA125 Johnson &amp; Johnson Vitros (JJC/JJ1) mean:</b>						
mean	17.5	28.3	50.4	36.3	27.4		mean	13.4	25.4	46.6	31.2	23.4	
SD	2.7	2.4	5.8	2.7	3.0		SD	1.7	2.6	5.3	3.1	2.8	
%CV	15.2%	8.6%	11.4%	7.3%	10.9%		%CV	12.6%	10.2%	11.4%	10.0%	12.0%	
N	3	3	3	3	3		N	7	7	7	7	7	
mean+3SD	25.5	35.6	67.8	44.3	36.3		mean+3SD	18.5	33.2	62.6	40.6	31.9	
mean-3SD	9.5	21.0	33.1	28.3	18.4		mean-3SD	8.3	17.7	30.6	21.8	15.0	
kit median	16.8	27.2	47.2	35.4	26.0		kit median	13.2	25.1	46.0	32.2	22.8	
mean/all kit median	1.00	0.92	0.97	1.00	0.98	0.97	mean/all kit median	0.77	0.83	0.90	0.86	0.84	0.84
<b>CA125 Elecsys 1010/2010 &amp; E170 (BME &amp; BMR/BM1) mean:</b>							<b>CA125 Fujirebio/Centocor (GAA/CE1) mean:</b>						
mean	15.2	25.7	42.7	31.0	24.7		mean	13.1	21.9	37.7	30.9	21.8	
SD	1.3	1.8	2.3	1.9	1.4		N	2	2	2	2	2	
%CV	8.9%	6.8%	5.3%	6.2%	5.6%		mean/all kit median	0.75	0.71	0.72	0.85	0.78	0.76
N	15	15	15	15	15		<b>CA125 kit average:</b>						
mean+3SD	19.2	31.0	49.6	36.7	28.9		mean	17.5	30.4	52.3	37.0	28.0	
mean-3SD	11.1	20.4	35.9	25.2	20.5		SD	2.8	4.9	8.0	4.9	4.1	
kit median	15.2	25.8	43.1	31.1	25.3		all kit median	17.5	30.8	52.0	36.3	27.9	
mean/all kit median	0.87	0.84	0.82	0.85	0.89	0.85							

	TM156	TM157	TM158	TM159	TM160		TM156	TM157	TM158	TM159	TM160		
<b>CA27.29 all lab mean:</b>							<b>CA27.29 Bayer ADVIA-Centaur (COB/BA1) mean:</b>						
mean	16.7	26.8	47.5	40.8	63.5		mean	16.1	26.6	47.1	40.4	62.7	
SD	3.2	3.9	5.2	4.9	4.8		SD	2.8	3.2	5.6	5.2	3.7	
%CV	19.0%	14.4%	11.0%	11.9%	7.6%		%CV	17.5%	11.9%	11.8%	12.9%	5.9%	
N	51	52	52	52	52		N	41	41	42	42	41	
mean+3SD	26.3	38.4	63.2	55.4	77.9		mean+3SD	24.5	36.1	63.8	56.1	73.9	
mean-3SD	7.2	15.2	31.8	26.2	49.1		mean-3SD	7.6	17.1	30.4	24.8	51.6	
mean/all kit median	0.88	0.92	0.97	0.97	0.95	0.94	kit median	15.7	26.8	48.8	41.3	63.0	
							mean/all kit median	0.85	0.92	0.96	0.96	0.94	0.92
<b>CA27.29 TOSOH ST A1A-pack (TOM/TO2) mean:</b>							<b>CA27.29 Bayer ACS-180 (COS/BA1) mean:</b>						
mean	21.9	31.4	49.9	43.5	69.5		mean	15.8	25.6	47.9	41.1	63.7	
SD	1.4	2.3	2.1	1.7	0.7		SD	1.8	4.5	5.0	2.9	3.9	
%CV	6.4%	7.3%	4.2%	3.9%	1.0%		%CV	11.4%	17.8%	10.3%	7.1%	6.1%	
N	3	3	3	3	3		N	4	4	4	4	4	
mean+3SD	26.1	38.3	56.2	48.5	71.6		mean+3SD	21.1	39.2	62.8	49.9	75.4	
mean-3SD	17.7	24.6	43.6	38.5	67.3		mean-3SD	10.4	11.9	33.1	32.3	51.9	
kit median	21.8	32.7	49.7	42.9	69.6		kit median	15.4	24.1	48.5	40.7	63.4	
mean/all kit median	1.15	1.08	1.02	1.03	1.04	1.07	mean/all kit median	0.83	0.88	0.98	0.97	0.96	0.92
<b>CA27.29 TOSOH AIA (TOM/TO1) mean:</b>							<b>CA27.29 kit average:</b>						
mean	22.1	31.8	50.3	44.5	73.0		mean	19.0	28.8	48.8	42.4	67.2	
N	2	2	2	2	2		SD	3.5	3.2	1.5	1.9	4.9	
mean/all kit median	1.16	1.10	1.03	1.05	1.10	1.09	all kit median	19.0	29.0	48.9	42.3	66.6	

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CA15-3 all lab mean:</b>							<b>CA15-3 Johnson &amp; Johnson (JJC/JJ1) mean:</b>						
mean	25.9	37.4	59.2	51.8	71.1		mean	20.5	29.2	47.1	41.5	54.3	
SD	7.7	12.0	19.3	16.0	35.0		SD	1.0	1.5	3.0	1.7	2.5	
%CV	29.6%	32.1%	32.6%	30.9%	49.2%		%CV	4.8%	5.2%	6.3%	4.2%	4.6%	
N	50	50	50	50	50		N	3	3	3	3	3	
mean+3SD	48.8	73.4	117.1	99.9	176.0		mean+3SD	23.4	33.7	56.0	46.7	61.9	
mean-3SD	2.9	1.4	1.3	3.7	-33.8		mean-3SD	17.5	24.7	38.2	36.3	46.8	
mean/all kit median	1.19	1.19	1.22	1.20	1.24	1.21	kit median	20.0	28.7	47.4	41.1	54.0	
							mean/all kit median	0.94	0.93	0.97	0.96	0.95	0.95
<b>CA15-3 DPC Immulite 1000/2000 (DPB &amp; DPD/DP5) mean:</b>							<b>CA15-3 Beckman Unicel &amp; Access (BCU &amp; BCX/BC1) mean:</b>						
mean	40.1	59.7	93.8	81.0	136.8		mean	19.7	27.6	43.6	38.0	58.2	
SD	3.0	4.2	8.4	6.2	9.5		SD	0.7	1.1	1.6	1.4	2.6	
%CV	7.4%	7.1%	9.0%	7.7%	6.9%		%CV	3.6%	3.9%	3.6%	3.6%	4.4%	
N	9	9	9	9	9		N	5	5	5	5	5	
mean+3SD	49.0	72.4	119.1	99.6	165.2		mean+3SD	21.8	30.9	48.3	42.1	65.8	
mean-3SD	31.2	47.0	68.5	62.4	108.4		mean-3SD	17.5	24.3	38.9	33.9	50.5	
kit median	39.9	58.6	91.8	81.0	140.0		kit median	19.3	27.2	43.2	38.1	57.3	
mean/all kit median	1.85	1.90	1.93	1.87	2.39	1.99	mean/all kit median	0.91	0.88	0.90	0.88	1.02	0.92
<b>CA15-3 Bayer ADVIA-Centaur (COB/BA1) mean:</b>							<b>CA15-3 Roche Elecsys (BME &amp; BMR/BM1) mean:</b>						
mean	24.1	35.1	57.0	49.3	57.8		mean	20.2	28.9	44.5	39.4	43.6	
SD	1.9	2.9	3.9	3.9	3.9		SD	0.8	1.1	1.7	0.5	1.6	
%CV	7.7%	8.3%	6.8%	7.9%	6.8%		%CV	3.9%	3.8%	3.9%	1.2%	3.7%	
N	19	19	19	19	19		N	6	6	6	6	6	
mean+3SD	29.6	43.8	68.6	61.0	69.6		mean+3SD	22.6	32.2	49.7	40.9	48.5	
mean-3SD	18.5	26.4	45.4	37.6	46.0		mean-3SD	17.9	25.6	39.3	38.0	38.8	
kit median	23.9	34.9	57.0	50.1	58.7		kit median	20.5	28.9	44.7	39.4	43.5	
mean/all kit median	1.11	1.12	1.18	1.14	1.01	1.11	mean/all kit median	0.93	0.92	0.92	0.91	0.76	0.89
<b>CA15-3 Abbott Asxym (ABB/AB1) mean:</b>							<b>CA15-3 kit average:</b>						
mean	22.9	33.5	49.9	44.9	56.6		mean	24.6	35.7	56.0	49.0	67.9	
SD	2.2	2.2	6.5	3.8	7.1		SD	7.8	12.1	19.1	16.2	34.2	
%CV	9.6%	6.7%	12.9%	8.4%	12.6%		all kit median	21.7	31.3	48.5	43.2	57.2	
N	5	5	5	5	5								
mean+3SD	29.4	40.2	69.2	56.2	77.9								
mean-3SD	16.3	26.7	30.5	33.6	35.2								
kit median	23.5	32.7	48.5	43.2	54.8								
mean/all kit median	1.06	1.07	1.03	1.04	0.99	1.04							

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CA19-9 all lab mean:</b>							<b>CA19-9 Beckman Unicel (BCU/BC1) mean:</b>						
mean	22.8	48.2	39.9	34.2	48.0		mean	18.0	38.8	30.6	25.9	37.8	
SD	6.0	11.8	10.0	8.3	10.4		SD	1.5	3.4	2.3	1.9	3.5	
%CV	26.2%	24.5%	25.1%	24.2%	21.6%		%CV	8.4%	8.9%	7.6%	7.3%	9.2%	
mean+3SD	40.7	83.6	69.8	59.0	79.1		mean+3SD	22.6	49.2	37.6	31.5	48.3	
mean-3SD	4.9	12.7	9.9	9.4	16.8		mean-3SD	13.5	28.5	23.6	20.2	27.3	
N	52	52	52	52	52		N	5	5	5	5	5	
mean/all kit median	1.31	1.30	1.29	1.28	1.23	1.28	kit median	18.0	39.0	30.1	27.0	39.3	
							mean/all kit median	1.04	1.05	0.99	0.97	0.97	1.00
<b>CA19-9 Fujirebio/Centocor (GAA/CE1) mean:</b>							<b>CA19-9 TOSOH A1A (TOM/TO1) mean:</b>						
mean	32.2	58.3	52.9	44.7	60.5		mean	16.9	32.1	31.8	27.4	42.9	
N	2	2	2	2	2		N	2	2	2	2	2	
mean/all kit median	1.85	1.57	1.71	1.68	1.55	1.67	mean/all kit median	0.97	0.86	1.03	1.03	1.10	1.00
<b>CA19-9 Bayer ADVIA-Centaur (COB/BA1) mean:</b>							<b>CA19-9 DPC Immulite (DPD/DP5) mean:</b>						
mean	26.6	56.7	46.6	39.8	54.9		mean	15.4	37.1	27.3	23.9	33.9	
SD	3.3	5.3	5.3	4.2	5.6		SD	1.1	1.9	2.6	2.1	0.9	
%CV	12.5%	9.4%	11.4%	10.7%	10.1%		%CV	7.2%	5.1%	9.6%	8.6%	2.5%	
mean+3SD	36.6	72.6	62.6	52.6	71.6		mean+3SD	18.7	42.7	35.2	30.1	36.5	
mean-3SD	16.6	40.8	30.7	27.1	38.3		mean-3SD	12.1	31.4	19.4	17.7	31.4	
N	29	29	29	29	29		N	3	3	3	3	3	
kit median	26.8	56.3	47.4	39.7	55.2		kit median	15.6	38.1	26.6	24.5	33.6	
mean/all kit median	1.53	1.53	1.50	1.50	1.41	1.49	mean/all kit median	0.89	1.00	0.88	0.90	0.87	0.91
<b>CA19-9 Roche Elecsys &amp; E170 (BME &amp; BMR/BM1) mean:</b>							<b>CA19-9 Beckman Access (BCX/BC1) mean:</b>						
mean	17.9	37.1	31.4	27.4	40.3		mean	15.7	34.7	27.8	24.5	33.3	
SD	1.5	1.6	2.3	1.1	2.5		SD	1.9	3.9	2.1	3.1	4.0	
%CV	8.5%	4.3%	7.4%	3.8%	6.1%		%CV	12.1%	11.2%	7.6%	12.6%	12.1%	
mean+3SD	22.5	41.9	38.4	30.6	47.6		mean+3SD	21.4	46.4	34.1	33.8	45.4	
mean-3SD	13.3	32.3	24.5	24.3	32.9		mean-3SD	10.0	23.0	21.5	15.2	21.2	
N	5	5	5	5	5		N	4	4	4	4	4	
kit median	17.9	36.4	30.8	27.6	40.9		kit median	16.3	35.5	28.4	25.1	34.6	
mean/all kit median	1.03	1.00	1.01	1.03	1.03	1.02	mean/all kit median	0.90	0.94	0.90	0.92	0.85	0.90
<b>CA19-9 kit average:</b>							<b>CA19-9 TOSOH ST-A1A (TOM/TO2) mean:</b>						
mean	19.5	40.0	34.1	29.3	42.3		mean	13.5	25.4	24.1	21.2	34.4	
SD	6.4	11.6	10.1	8.3	10.2		N	2	2	2	2	2	
all kit median	17.4	37.1	31.0	26.6	39.1		mean/all kit median	0.78	0.68	0.78	0.79	0.88	0.78

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CEA all lab mean:</b>							<b>CEA DPC Immulite 2000 (DPD/DP5) mean:</b>						
mean	4.4	20.9	14.8	9.8	10.2		mean	4.8	24.7	17.4	11.1	11.7	
SD	0.5	2.5	1.8	1.2	1.2		SD	0.4	1.6	1.1	0.7	0.8	
%CV	11.3%	11.9%	12.4%	12.0%	11.5%		%CV	8.0%	6.5%	6.2%	6.7%	6.9%	
mean+3SD	5.8	28.4	20.3	13.3	13.8		mean+3SD	6.0	29.5	20.6	13.3	14.1	
mean-3SD	2.9	13.4	9.3	6.3	6.7		mean-3SD	3.7	19.9	14.1	8.9	9.2	
N	174	175	175	176	175		N	16	16	16	16	16	
mean/all kit median	1.00	0.97	1.01	0.98	0.98	0.99	kit median	4.9	24.8	17.1	11.0	11.4	
							mean/all kit median	1.11	1.14	1.19	1.11	1.12	1.13
<b>CEA TOSOH ST-AIA (TOM/TO2) mean:</b>							<b>CEA DPC Immulite 1000 (DPB/DP5) mean:</b>						
mean	6.7	30.6	21.2	14.8	15.5		mean	4.3	24.2	16.3	10.4	10.9	
SD	0.1	0.8	0.5	0.3	0.4		SD	0.1	0.5	0.4	0.4	0.5	
%CV	0.9%	2.5%	2.4%	1.8%	2.4%		%CV	1.3%	2.0%	2.2%	3.4%	4.7%	
mean+3SD	6.8	32.9	22.7	15.6	16.7		mean+3SD	4.5	25.7	17.3	11.5	12.4	
mean-3SD	6.5	28.2	19.7	14.0	14.4		mean-3SD	4.2	22.8	15.2	9.4	9.3	
N	3	3	3	3	3		N	3	3	3	3	3	
kit median	6.7	30.8	21.3	14.7	15.7		kit median	4.3	24.0	16.3	10.4	11.0	
mean/all kit median	1.53	1.42	1.45	1.48	1.49	1.48	mean/all kit median	1.00	1.12	1.11	1.04	1.04	1.06
<b>CEA TOSOH AIA (TOM/TO1) mean:</b>							<b>CEA Bayer ADVIA-Centaur (COB/BA1) mean:</b>						
mean	5.5	24.2	17.1	11.5	12.6		mean	4.6	22.1	15.8	10.5	10.8	
SD	0.3	1.0	0.3	0.5	0.5		SD	0.3	1.2	0.9	0.6	0.6	
%CV	5.4%	4.1%	1.7%	4.7%	3.9%		%CV	6.1%	5.4%	5.8%	5.8%	5.1%	
mean+3SD	6.4	27.2	18.0	13.1	14.1		mean+3SD	5.5	25.7	18.6	12.4	12.5	
mean-3SD	4.6	21.2	16.2	9.9	11.1		mean-3SD	3.8	18.5	13.1	8.7	9.2	
N	4	4	4	4	4		N	56	58	57	57	57	
kit median	5.5	23.8	17.1	11.5	12.6		kit median	4.6	22.1	15.7	10.5	10.8	
mean/all kit median	1.26	1.12	1.17	1.15	1.21	1.18	mean/all kit median	1.06	1.02	1.08	1.05	1.04	1.05
<b>CEA DPC Immulite 2500 (DPF/DP5) mean:</b>							<b>CEA Bayer ACS-180 (COS/BA1) mean:</b>						
mean	4.9	25.1	17.2	11.1	12.3		mean	4.6	22.0	16.1	10.4	10.4	
N	2	2	2	2	2		SD	0.3	2.3	1.0	0.6	1.3	
mean/all kit median	1.11	1.16	1.18	1.11	1.18	1.15	%CV	6.6%	10.4%	6.1%	6.1%	12.0%	
							mean+3SD	5.5	28.9	19.0	12.3	14.2	
							mean-3SD	3.7	15.1	13.1	8.5	6.6	
							N	3	3	3	3	3	
							kit median	4.7	21.1	15.6	10.8	10.5	
							mean/all kit median	1.07	1.02	1.10	1.04	1.00	1.05

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>CEA Abbott IMx (ABM/AB1) mean:</b>							<b>CEA Beckman Access (BCX/BC1) mean:</b>						
mean	4.4	21.6	14.5	10.0	11.0		mean	3.9	18.3	13.3	8.9	9.0	
N	2	2	2	2	2		SD	0.2	0.8	0.7	0.4	0.4	
mean/all kit median	1.00	1.00	0.99	1.00	1.06	1.01	%CV	5.4%	4.3%	5.4%	4.8%	4.4%	
							mean+3SD	4.6	20.6	15.5	10.2	10.2	
							mean-3SD	3.3	15.9	11.2	7.6	7.8	
<b>CEA Abbott Architect (ABH/AB1) mean:</b>							<b>CEA Roche Elecsys E170 (BMR/BM1) mean:</b>						
mean	4.6	21.0	14.6	9.3	10.2		mean	3.9	17.7	12.3	8.2	9.0	
N	2	2	2	2	2		SD	0.2	0.7	0.5	0.3	0.3	
mean/all kit median	1.06	0.97	1.00	0.93	0.98	0.99	%CV	5.0%	4.0%	4.0%	3.6%	3.6%	
							mean+3SD	4.5	19.8	13.7	9.1	9.9	
							mean-3SD	3.3	15.6	10.8	7.3	8.0	
							N	10	10	10	10	10	
							kit median	3.9	17.6	12.4	8.3	9.1	
							mean/all kit median	0.90	0.82	0.84	0.82	0.86	0.85
<b>CEA Abbott Asxym (ABB/AB1) mean:</b>							<b>CEA Roche Elecsys 1010/2010 (BME/BM1) mean:</b>						
mean	4.3	21.3	14.4	9.6	10.2		mean	3.9	17.2	12.2	8.2	8.8	
SD	0.4	1.5	1.3	0.7	1.2		SD	0.2	0.7	0.4	0.3	0.4	
%CV	9.6%	7.2%	9.3%	7.0%	11.4%		%CV	4.8%	3.8%	3.4%	4.2%	4.6%	
mean+3SD	5.6	25.8	18.5	11.7	13.7		mean+3SD	4.5	19.2	13.4	9.3	10.0	
mean-3SD	3.1	16.7	10.4	7.6	6.7		mean-3SD	3.3	15.3	10.9	7.2	7.6	
N	24	24	24	23	24		N	13	13	13	13	13	
kit median	4.4	21.3	14.8	9.9	10.4		kit median	3.8	17.2	12.1	8.2	8.8	
mean/all kit median	0.99	0.98	0.99	0.96	0.98	0.98	mean/all kit median	0.90	0.80	0.83	0.82	0.84	0.84
<b>CEA Johnson &amp; Johnson Vitros Eci (JJC/JJ1) mean:</b>							<b>CEA kit average:</b>						
mean	3.7	20.0	13.9	9.2	9.8		mean	4.5	21.9	15.3	10.1	10.7	
SD	0.3	0.9	0.7	0.3	0.5		SD	0.8	3.5	2.4	1.7	1.8	
%CV	6.8%	4.8%	4.8%	2.8%	5.4%		all kit median	4.4	21.6	14.6	10.0	10.4	
mean+3SD	4.4	22.8	15.9	10.0	11.4								
mean-3SD	2.9	17.1	11.9	8.5	8.2								
N	10	10	10	10	10								
kit median	3.8	20.0	14.0	9.2	9.9								
mean/all kit median	0.85	0.92	0.95	0.92	0.95	0.92							
<b>CEA Beckman Unicel (BCU/BC1) mean:</b>													
mean	4.0	18.6	13.4	8.6	9.0								
SD	0.2	1.4	1.2	0.6	0.6								
%CV	6.2%	7.4%	9.1%	7.0%	6.5%								
mean+3SD	4.7	22.7	17.0	10.4	10.8								
mean-3SD	3.2	14.5	9.7	6.8	7.3								
N	11	11	11	11	11								
kit median	4.0	18.2	12.9	8.7	9.1								
mean/all kit median	0.91	0.86	0.92	0.86	0.87	0.88							

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>AFP all lab mean:</b>							<b>AFP TOSOH ST-A1A (TOM/TO2) mean:</b>						
mean	11.5	7.0	13.9	55.2	28.5		mean	11.5	6.9	13.9	57.0	29.5	
SD	0.9	0.6	1.0	3.9	2.1		SD	0.7	0.4	1.0	2.7	1.8	
%CV	7.8%	8.7%	7.2%	7.0%	7.4%		%CV	5.7%	6.0%	7.2%	4.8%	6.0%	
mean+3SD	14.2	8.8	16.9	66.9	34.9		mean+3SD	13.4	8.2	16.9	65.2	34.7	
mean-3SD	8.8	5.1	10.9	43.5	22.2		mean-3SD	9.5	5.7	10.9	48.9	24.2	
N	97	97	96	97	97		N	3	3	3	3	3	
mean/target	1.04	1.10	1.08	1.05	1.05	1.06	kit median	11.5	6.8	14.0	56.1	29.3	
							mean/target	1.03	1.10	1.09	1.08	1.08	1.08
<b>AFP Bayer ACS 180 (COS/BA1) mean:</b>							<b>AFP Roche E170 (BMR/BM1) mean:</b>						
mean	13.2	7.8	15.8	57.2	31.2		mean	11.4	6.8	13.8	57.2	28.7	
N	2	2	2	2	2		SD	0.6	0.4	0.8	2.4	1.7	
mean/target	1.19	1.24	1.23	1.08	1.14	1.18	%CV	5.5%	6.3%	5.9%	4.2%	5.8%	
							mean+3SD	13.3	8.1	16.3	64.3	33.7	
							mean-3SD	9.5	5.5	11.4	50.0	23.7	
<b>AFP Beckman Access (BCX/BC1) mean:</b>							N	8	8	8	8	8	
mean	12.2	7.3	14.8	58.9	30.0		kit median	11.6	6.9	14.0	57.6	28.9	
SD	0.9	0.5	1.0	5.6	3.1		mean/target	1.02	1.09	1.08	1.08	1.05	1.06
%CV	7.0%	6.7%	7.1%	9.4%	10.4%								
mean+3SD	14.8	8.7	17.9	75.6	39.3		<b>AFP DPC Immulite 1000 (DPB/DP5) mean:</b>						
mean-3SD	9.7	5.8	11.6	42.2	20.7		mean	11.1	6.8	13.8	54.9	28.8	
N	5	5	5	5	5		SD	0.2	0.2	0.9	2.0	1.0	
kit median	12.3	7.2	14.8	60.0	30.0		%CV	2.1%	3.1%	6.7%	3.7%	3.4%	
mean/target	1.10	1.16	1.15	1.12	1.10	1.13	mean+3SD	11.8	7.4	16.5	60.9	31.7	
							mean-3SD	10.4	6.1	11.0	48.9	25.8	
<b>AFP Bayer ADVIDA Centaur (COB/BA1) mean:</b>							N	3	3	3	3	3	
mean	12.0	7.4	14.2	54.9	29.3		kit median	11.2	6.7	14.3	55.6	28.3	
SD	0.8	0.7	0.8	2.4	1.1		mean/target	1.00	1.07	1.08	1.04	1.05	1.05
%CV	6.6%	9.0%	5.7%	4.4%	3.6%								
mean+3SD	14.4	9.4	16.7	62.1	32.5		<b>AFP DPC Immulite 2000 (DPD/DP5) mean:</b>						
mean-3SD	9.6	5.4	11.8	47.7	26.1		mean	11.4	6.7	13.8	54.7	28.0	
N	25	25	25	25	25		SD	0.4	0.4	0.9	3.2	1.6	
kit median	12.1	7.4	14.4	54.8	29.0		%CV	3.3%	5.3%	6.5%	5.9%	5.8%	
mean/target	1.08	1.18	1.11	1.04	1.07	1.10	mean+3SD	12.5	7.8	16.6	64.3	32.8	
							mean-3SD	10.3	5.6	11.1	45.0	23.1	
<b>AFP Beckman Unicel (BCU/BC1) mean:</b>							N	18	18	17	18	18	
mean	11.7	7.0	14.2	58.6	29.6		kit median	11.3	6.7	14.0	54.3	27.9	
SD	1.3	0.5	0.5	4.4	2.6		mean/target	1.03	1.06	1.08	1.04	1.02	1.05
%CV	11.1%	6.8%	3.3%	7.5%	8.6%								
mean+3SD	15.5	8.4	15.6	71.7	37.3								
mean-3SD	7.8	5.6	12.8	45.5	22.0								
N	9	9	9	9	9								
kit median	11.7	6.9	14.0	57.6	29.4								
mean/target	1.05	1.11	1.11	1.11	1.09	1.09							

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias	TM156	TM157	TM158	TM159	TM160	Average bias	
<b>AFP Roche Elecsys 1010/2010 (BME/BM1) mean:</b>							<b>AFP Johnson &amp; Johnson Vitros Eci (JJC/JJ1) mean:</b>						
mean	10.7	6.8	13.6	54.6	26.7		mean	9.9	6.1	11.4	45.2	23.1	
SD	0.4	0.3	0.4	0.8	0.9		SD	0.2	0.2	0.2	0.9	0.1	
%CV	4.2%	3.9%	2.6%	1.5%	3.5%		%CV	2.1%	3.4%	1.3%	2.0%	0.5%	
mean+3SD	12.1	7.6	14.7	57.1	29.5		mean+3SD	10.6	6.8	11.8	47.9	23.5	
mean-3SD	9.4	6.0	12.5	52.0	23.9		mean-3SD	9.3	5.5	10.9	42.5	22.8	
N	4	4	4	4	4		N	3	3	3	3	3	
kit median	10.9	6.8	13.7	54.2	26.6		kit median	10.0	6.2	11.4	45.7	23.2	
mean/target	0.97	1.08	1.06	1.03	0.98	1.02	mean/target	0.89	0.97	0.89	0.86	0.85	0.89
<b>AFP Abbott Asxym (ABB/AB1) mean:</b>							<b>AFP kit average:</b>						
mean	11.0	6.7	13.3	53.4	27.6		mean	11.5	6.9	13.9	55.1	28.4	
SD	0.6	0.4	0.8	3.8	2.2		SD	0.9	0.4	1.1	3.7	2.1	
%CV	5.9%	6.4%	6.1%	7.2%	8.0%		all kit median	11.4	6.8	13.8	54.9	28.8	
mean+3SD	13.0	7.9	15.7	65.0	34.2		mean/target	1.04	1.10	1.09	1.04	1.04	1.06
mean-3SD	9.1	5.4	10.9	41.9	21.0		<b>AFP</b>						
N	15	15	15	15	15			<b>TM156</b>	<b>TM157</b>	<b>TM158</b>	<b>TM159</b>	<b>TM160</b>	
kit median	11.1	6.7	13.5	52.2	27.6		<b>*IS target</b>	<b>11.1</b>	<b>6.3</b>	<b>12.8</b>	<b>52.8</b>	<b>27.3</b>	
mean/target	0.99	1.06	1.04	1.01	1.01	1.02	<b>SD ( +/- )</b>	1.29	0.79	1.35	3.01	1.77	
							<b>% CV</b>	11.7%	12.4%	10.6%	5.7%	6.5%	
							<b>high (30%)</b>	14.4	8.2	16.6	68.6	35.4	
							<b>low (30%)</b>	7.8	4.4	9.0	36.9	19.1	
							* target value from a traceable AFP standard						

	TM156	TM157	TM158	TM159	TM160	Average bias	TM156	TM157	TM158	TM159	TM160	Average bias	
<b>PSA all lab mean:</b>							<b>PSA Abbott IMX Mono/mono (ABM/AB2) mean:</b>						
mean	4.0	1.5	6.9	6.7	9.7		mean	4.2	1.6	7.1	6.8	9.8	
SD	0.3	0.1	0.6	0.5	0.8		N	2	2	2	2	2	
%CV	8.5%	9.8%	8.5%	8.1%	8.0%		mean/target	1.15	1.11	1.10	1.08	1.11	1.11
mean+3SD	5.0	1.9	8.7	8.3	12.0								
mean-3SD	2.9	1.0	5.2	5.0	7.4								
N	272	272	272	272	272								
mean/target	1.10	1.05	0.97	0.95	0.99	1.01							
<b>PSA Johnson &amp; Johnson Vitros Eci (JJC/JJ1) mean:</b>							<b>PSA Beckman Access (BCX/BC1) mean:</b>						
mean	4.6	1.9	7.7	7.2	10.1		mean	4.3	1.6	7.6	7.4	10.6	
SD	0.2	0.1	0.3	0.3	0.4		SD	0.2	0.1	0.3	0.3	0.5	
%CV	5.2%	4.3%	3.7%	4.1%	3.5%		%CV	4.7%	5.3%	3.8%	4.5%	4.3%	
mean+3SD	5.3	2.1	8.6	8.1	11.2		mean+3SD	4.9	1.8	8.5	8.4	12.0	
mean-3SD	3.8	1.6	6.9	6.3	9.1		mean-3SD	3.7	1.3	6.7	6.4	9.3	
N	12	12	12	12	12		N	43	43	43	43	43	
kit median	4.6	1.9	7.8	7.2	10.1		kit median	4.3	1.6	7.6	7.4	10.6	
mean/target	1.27	1.32	1.09	1.03	1.03	1.15	mean/target	1.18	1.13	1.07	1.05	1.09	1.11

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>PSA Beckman Unicel (BCU/BC1) mean:</b>							<b>PSA Dade Behring Dimension (DUD/DA1) mean:</b>						
mean	4.2	1.6	7.4	7.1	10.4		mean	3.9	1.4	6.7	6.5	9.5	
SD	0.2	0.1	0.4	0.5	0.4		SD	0.2	0.1	0.4	0.4	0.6	
%CV	4.8%	4.0%	5.0%	6.7%	4.3%		%CV	6.1%	6.8%	5.5%	5.8%	6.1%	
mean+3SD	4.8	1.8	8.5	8.5	11.8		mean+3SD	4.6	1.7	7.8	7.6	11.2	
mean-3SD	3.6	1.4	6.3	5.7	9.1		mean-3SD	3.2	1.1	5.6	5.4	7.7	
N	14	14	14	14	14		N	26	26	26	26	26	
kit median	4.3	1.6	7.4	7.2	10.6		kit median	3.9	1.4	6.8	6.5	9.6	
mean/target	1.17	1.12	1.04	1.02	1.07	1.08	mean/target	1.09	1.03	0.94	0.93	0.97	0.99
<b>PSA TOSOH AIA (TOM/TO1) mean:</b>							<b>PSA DPC Immulite 2500 (DPF/DP5) mean:</b>						
mean	4.2	1.6	7.4	7.0	10.1		mean	3.8	1.3	6.3	6.1	8.9	
SD	0.2	0.1	0.3	0.4	0.5		N	2	2	2	2	2	
%CV	5.9%	5.8%	4.7%	5.1%	5.2%		mean/target	1.06	0.93	0.98	0.96	1.01	0.99
mean+3SD	4.9	1.8	8.4	8.0	11.7								
mean-3SD	3.4	1.3	6.3	5.9	8.5								
N	11	11	11	11	11								
kit median	4.1	1.6	7.4	7.0	10.1								
mean/target	1.15	1.12	1.04	0.99	1.03	1.07							
<b>PSA TOSOH ST-AIA (TOM/TO2) mean:</b>							<b>PSA DPC Immulite 1000 (DPB/DP5) mean:</b>						
mean	4.1	1.5	7.1	7.0	10.0		mean	3.9	1.3	6.7	6.8	9.7	
SD	0.2	0.1	0.3	0.3	0.8		SD	0.2	0.1	0.4	0.4	0.4	
%CV	5.1%	3.9%	3.7%	3.6%	7.5%		%CV	5.1%	11.2%	6.3%	5.2%	4.2%	
mean+3SD	4.7	1.6	7.9	7.7	12.3		mean+3SD	4.5	1.8	7.9	7.8	10.9	
mean-3SD	3.4	1.3	6.3	6.2	7.7		mean-3SD	3.3	0.9	5.4	5.7	8.4	
N	3	3	3	3	3		N	13	13	13	13	13	
kit median	4.0	1.5	7.2	7.0	9.9		kit median	3.8	1.3	6.8	6.9	9.6	
mean/target	1.13	1.05	1.00	1.00	1.02	1.04	mean/target	1.07	0.95	0.94	0.97	0.99	0.98
<b>PSA Bayer ACS180 (COS/BA2) mean:</b>							<b>PSA DPC Immulite 1000 &amp; 2000 3G (DPB &amp; DPD/DP6) mean:</b>						
mean	4.1	1.6	7.1	6.7	9.7		mean	3.8	1.5	6.9	6.3	9.2	
SD	0.3	0.1	0.2	0.3	0.2		SD	0.3	0.1	0.4	0.4	0.8	
%CV	8.4%	6.5%	2.5%	3.9%	2.2%		%CV	6.6%	3.9%	5.9%	6.4%	8.7%	
mean+3SD	5.1	1.9	7.6	7.5	10.3		mean+3SD	4.6	1.6	8.1	7.5	11.6	
mean-3SD	3.1	1.2	6.5	5.9	9.0		mean-3SD	3.1	1.3	5.7	5.1	6.8	
N	4	4	4	4	4		N	3	3	3	3	3	
kit median	4.2	1.6	7.1	6.7	9.7		kit median	3.8	1.5	6.8	6.2	9.3	
mean/target	1.13	1.11	0.99	0.96	0.98	1.04	mean/target	1.06	1.05	0.97	0.90	0.94	0.98

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>PSA Roche E170 (BMR/BM1) mean:</b>							<b>PSA Roche Elecsys (BME/BM1) mean:</b>						
mean	3.8	1.4	6.6	6.5	9.4		mean	3.7	1.4	6.4	6.3	9.1	
SD	0.2	0.1	0.3	0.3	0.4		SD	0.1	0.1	0.2	0.2	0.4	
%CV	4.7%	5.2%	4.3%	4.3%	4.2%		%CV	3.2%	5.0%	3.5%	3.9%	4.2%	
mean+3SD	4.3	1.7	7.5	7.3	10.6		mean+3SD	4.0	1.6	7.1	7.0	10.2	
mean-3SD	3.3	1.2	5.8	5.7	8.2		mean-3SD	3.3	1.2	5.7	5.6	7.9	
N	14	14	14	14	14		N	19	19	19	19	19	
kit median	3.8	1.5	6.7	6.5	9.5		kit median	3.6	1.4	6.4	6.3	9.0	
mean/target	1.06	1.03	0.93	0.93	0.96	0.98	mean/target	1.02	0.99	0.90	0.90	0.93	0.95
<b>PSA Bayer ADVIA-Centaur (COB/BA2) mean:</b>							<b>PSA DPC Immulite 2000 (DPD/DP5) mean:</b>						
mean	3.8	1.4	6.6	6.4	9.2		mean	3.7	1.3	6.6	6.4	9.3	
SD	0.2	0.1	0.5	0.4	0.6		SD	0.3	0.1	0.3	0.3	0.6	
%CV	6.3%	6.4%	7.1%	6.2%	6.8%		%CV	7.0%	5.3%	4.2%	4.8%	6.3%	
mean+3SD	4.5	1.7	8.0	7.5	11.1		mean+3SD	4.5	1.5	7.4	7.3	11.1	
mean-3SD	3.1	1.2	5.2	5.2	7.3		mean-3SD	2.9	1.1	5.7	5.5	7.6	
N	53	54	53	54	54		N	17	17	17	17	17	
kit median	3.8	1.5	6.6	6.2	9.2		kit median	3.6	1.3	6.5	6.4	9.4	
mean/target	1.05	1.03	0.93	0.91	0.94	0.97	mean/target	1.02	0.94	0.92	0.91	0.95	0.95
<b>PSA Abbott Asxym Mono/mono (ABB/AB2) mean:</b>							<b>PSA</b>						
mean	3.8	1.4	6.8	6.3	9.2		<b>* Assigned IS target</b>	<b>3.6</b>	<b>1.3</b>	<b>6.4</b>	<b>6.3</b>	<b>8.8</b>	
SD	0.4	0.1	0.6	0.6	0.9		<b>SD ( +/- )</b>	<b>0.2</b>	<b>0.1</b>	<b>0.3</b>	<b>0.4</b>	<b>0.3</b>	
%CV	10.5%	8.7%	9.4%	9.5%	9.9%		<b>% CV</b>	<b>4.4%</b>	<b>3.6%</b>	<b>4.6%</b>	<b>5.5%</b>	<b>3.6%</b>	
mean+3SD	5.0	1.8	8.7	8.1	12.0		<b>high (25%)</b>			8.0	7.9	11.0	
mean-3SD	2.6	1.0	4.9	4.5	6.5		<b>low (25%)</b>			4.8	4.7	6.6	
N	28	28	28	28	28		<b>high (30%)</b>	4.7	1.7				
kit median	3.9	1.4	6.9	6.5	9.4		<b>low (30%)</b>	2.5	0.9				
mean/target	1.07	1.00	0.95	0.90	0.94	0.97	* target value from a traceable PSA standard						
<b>PSA Abbott Architect Mono/mono (ABH/AB2) mean:</b>							<b>PSA kit average:</b>						
mean	3.8	1.4	6.5	6.4	9.3		mean	4.0	1.5	6.9	6.6	9.6	
SD	0.3	0.1	0.3	0.4	0.6		SD	0.2	0.1	0.4	0.4	0.5	
%CV	6.5%	7.0%	4.0%	5.8%	6.1%		all kit median	3.9	1.4	6.8	6.5	9.5	
mean+3SD	4.6	1.7	7.3	7.5	11.0								
mean-3SD	3.1	1.1	5.7	5.2	7.6								
N	4	4	4	4	4								
kit median	3.7	1.4	6.5	6.2	9.1								
mean/target	1.06	0.98	0.92	0.91	0.95	0.96							
										<b>mean</b>	<b>SD</b>		
							<b>Average Bias all labs</b>			1.019	0.063		
							<b>Average Bias Low Group (N=10)</b>			0.973	0.015		
							<b>Average Bias High Group (N=7)</b>			1.084	0.041		

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>PSA free all lab mean:</b>							<b>free PSA Roche E170 (BMR/BM2) mean:</b>						
mean	0.5	0.2	0.8	1.9	2.7		mean	0.38	0.16	0.66	1.56	2.32	
SD	0.1	0.0	0.2	0.4	0.5		SD	0.05	0.02	0.07	0.14	0.12	
%CV	21.3%	24.5%	23.6%	20.7%	18.7%		%CV	12.4%	10.2%	10.7%	8.7%	5.0%	
mean+3SD	0.8	0.3	1.4	3.1	4.3		mean+3SD	0.52	0.21	0.87	1.97	2.66	
mean-3SD	0.2	0.0	0.2	0.7	1.2		mean-3SD	0.24	0.11	0.45	1.15	1.97	
N	63	58	67	67	64		N	7	7	9	9	9	
mean/target	1.40	1.62	1.14	1.17	1.23	1.31	kit median	0.36	0.16	0.66	1.58	2.37	
							mean/target	1.16	1.43	0.91	0.96	1.03	1.10
<b>free PSA Beckman Unicel (BCU/BC1) mean:</b>							<b>free PSA Dade Behring Dimension (DUD/DA1) mean:</b>						
mean	0.54	0.22	0.99	2.20	3.20		mean	0.39	0.16	0.56	1.41	2.18	
SD	0.06	0.03	0.10	0.20	0.14		SD	0.04	0.03	0.19	0.18	0.17	
%CV	11.8%	13.5%	9.7%	8.9%	4.5%		%CV	9.6%	15.4%	33.3%	12.8%	8.0%	
mean+3SD	0.73	0.31	1.28	2.79	3.63		mean+3SD	0.50	0.24	1.13	1.96	2.70	
mean-3SD	0.35	0.13	0.70	1.61	2.77		mean-3SD	0.27	0.09	0.00	0.87	1.66	
N	12	12	12	12	12		N	5	4	5	5	5	
kit median	0.52	0.21	1.01	2.20	3.21		kit median	0.38	0.15	0.65	1.49	2.16	
mean/target	1.64	1.98	1.36	1.36	1.43	1.55	mean/target	1.17	1.48	0.77	0.87	0.97	1.05
<b>free PSA Beckman Access (BCX/BC1) mean:</b>							<b>free PSA Abbott Asxym (ABB/AB2) mean:</b>						
mean	0.54	0.21	1.00	2.28	3.29		mean	0.4	0.1	0.7	1.5	2.1	
SD	0.05	0.02	0.09	0.12	0.12		SD	0.1	0.0	0.0	0.1	0.1	
%CV	9.3%	9.6%	9.4%	5.3%	3.6%		%CV	14.0%	7.1%	6.7%	8.2%	5.0%	
mean+3SD	0.68	0.27	1.28	2.64	3.64		mean+3SD	0.5	0.2	0.8	1.9	2.4	
mean-3SD	0.39	0.15	0.71	1.91	2.93		mean-3SD	0.2	0.1	0.5	1.2	1.8	
N	22	17	22	22	19		N	3	3	4	4	4	
kit median	0.52	0.20	0.98	2.32	3.28		kit median	0.4	0.1	0.7	1.5	2.2	
mean/target	1.62	1.91	1.36	1.40	1.47	1.55	mean/target	1.11	1.27	0.93	0.94	0.95	1.04
<b>free PSA Roche Elecsys (BME/BM2) mean:</b>							<b>free PSA DPC Immulite 2000 (DPD/DP5) mean:</b>						
mean	0.39	0.15	0.74	1.63	2.38		mean	0.33	0.11	0.58	1.40	2.17	
SD	0.04	0.02	0.06	0.10	0.09		SD	0.05	0.02	0.09	0.06	0.22	
%CV	10.7%	13.5%	7.6%	6.4%	3.6%		%CV	13.8%	15.2%	16.3%	4.4%	10.4%	
mean+3SD	0.51	0.21	0.91	1.94	2.64		mean+3SD	0.47	0.16	0.86	1.58	2.84	
mean-3SD	0.26	0.09	0.57	1.31	2.13		mean-3SD	0.19	0.06	0.29	1.21	1.50	
N	8	8	9	9	9		N	4	4	4	4	4	
kit median	0.38	0.15	0.75	1.62	2.38		kit median	0.33	0.12	0.56	1.41	2.13	
mean/target	1.17	1.39	1.01	1.00	1.06	1.13	mean/target	1.00	1.02	0.79	0.86	0.97	0.93
<b>free PSA kit average:</b>							<b>free PSA</b>						
mean	0.38	0.15	0.68	1.55	2.27			<b>TM156</b>	<b>TM157</b>	<b>TM158</b>	<b>TM159</b>	<b>TM160</b>	
SD	0.14	0.06	0.26	0.58	0.85		<b>* IS target</b>	<b>0.33</b>	<b>0.11</b>	<b>0.73</b>	<b>1.62</b>	<b>2.24</b>	
all kit median	0.38	0.15	0.67	1.55	2.25		<b>SD ( +/- )</b>	<b>0.02</b>	<b>0.01</b>	<b>0.01</b>	<b>0.03</b>	<b>0.03</b>	
							<b>% CV</b>	<b>4.5%</b>	<b>4.4%</b>	<b>1.4%</b>	<b>1.9%</b>	<b>1.5%</b>	
							<b>high (30%)</b>	<b>0.43</b>	<b>0.14</b>	<b>0.95</b>	<b>2.11</b>	<b>2.91</b>	
							<b>low (30%)</b>	<b>0.23</b>	<b>0.08</b>	<b>0.51</b>	<b>1.13</b>	<b>1.57</b>	

\* target value from a traceable free PSA standard.

New York State Proficiency Test September 2006  
Summary of Results

	TM156	TM157	TM158	TM159	TM160	Average bias		TM156	TM157	TM158	TM159	TM160	Average bias
<b>%free PSA all lab mean:</b>							<b>% free PSA AB2/AB2 mean:</b>						
mean	11.4	12.2	11.7	27.3	26.7		mean	9.8	10.4	10.4	25.2	24.3	
SD	1.8	2.2	1.8	3.8	3.5		SD	0.4	0.5	0.5	2.0	2.8	
%CV	15.8%	18.2%	15.8%	14.0%	13.3%		%CV	3.6%	4.8%	5.0%	8.1%	11.6%	
mean+3SD	16.8	18.8	17.2	38.8	37.3		mean+3SD	10.8	11.8	11.9	31.3	32.8	
mean-3SD	6.0	5.5	6.1	15.8	16.0		mean-3SD	8.7	8.9	8.8	19.1	15.8	
N	54	37	60	61	46		N	2	2	4	4	4	
mean/target	1.21	1.38	1.02	1.04	1.05	1.14	kit median	9.8	10.4	10.2	24.9	23.5	
							mean/target	1.04	1.18	0.90	0.96	0.95	1.01
<b>% free PSA BC1/BC1 mean:</b>							<b>% free PSA DA1/DA1 mean:</b>						
mean	12.6	13.9	13.1	30.7	30.9		mean	9.9	11.0	9.9	22.1	22.8	
SD	1.2	1.6	1.2	1.3	0.8		SD	1.4	0.9	1.0	3.6	1.4	
%CV	9.7%	11.3%	9.0%	4.3%	2.7%		%CV	13.9%	7.9%	10.5%	16.4%	6.1%	
mean+3SD	16.3	18.6	16.7	34.7	33.4		mean+3SD	14.0	13.6	13.0	33.0	27.0	
mean-3SD	8.9	9.2	9.6	26.7	28.4		mean-3SD	5.8	8.4	6.8	11.2	18.6	
N	29	15	29	29	14		N	4	3	3	4	4	
kit median	12.1	14.0	13.3	31.0	31.0		kit median	9.7	10.6	9.4	23.0	22.8	
mean/target	1.34	1.58	1.14	1.17	1.21	1.29	mean/target	1.05	1.25	0.86	0.84	0.89	0.98
<b>% free PSA BM2/BM1 mean:</b>							<b>% free PSA DP5/DP5 mean:</b>						
mean	10.2	11.3	10.6	24.9	25.3		mean	8.4	8.3	8.1	22.2	21.8	
SD	1.1	1.5	1.1	1.8	1.8		SD	1.4	2.2	0.4	0.8	2.1	
%CV	10.9%	13.7%	10.3%	7.2%	7.0%		%CV	17.0%	26.6%	4.5%	3.7%	9.5%	
mean+3SD	13.6	16.0	13.9	30.2	30.7		mean+3SD	12.7	14.8	9.2	24.7	28.1	
mean-3SD	6.9	6.7	7.3	19.5	20.0		mean-3SD	4.1	1.7	7.0	19.7	15.6	
N	13	12	18	18	18		N	3	2	3	3	3	
kit median	10.0	11.2	10.6	25.0	24.9		kit median	8.1	8.3	8.0	22.5	22.2	
mean/target	1.09	1.29	0.92	0.94	0.99	1.05	mean/target	0.90	0.94	0.70	0.85	0.86	0.85
<b>% free PSA kit average:</b>							<b>% free PSA</b>						
mean	10.2	11.0	10.4	25.0	25.0								
SD	1.5	2.0	1.8	3.5	3.6								
all kit median	9.9	11.0	10.4	24.9	24.3								
							<b>IS target</b>	<b>9.4%</b>	<b>8.8%</b>	<b>11.5%</b>	<b>26.3%</b>	<b>25.5%</b>	

	TM156	TM157	TM158	TM159	TM160		TM156	TM157	TM158	TM159	TM160	
<b>PSA complexed all lab mean:</b>							<b>% complexed PSA all lab mean:</b>					
mean	3.5	1.3	6.0	4.9	7.0		mean	89.4	86.4	88.4	73.6	73.3
SD	0.2	0.1	0.5	0.4	0.4		SD	5.4	8.3	6.8	6.3	4.8
%CV	6.4%	8.7%	7.5%	7.5%	5.3%		%CV	6.0%	9.6%	7.7%	8.5%	6.5%
mean+3SD	4.2	1.6	7.4	6.0	8.1		mean+3SD	105.6	111.3	108.8	92.4	87.6
mean-3SD	2.8	1.0	4.7	3.8	5.8		mean-3SD	73.2	61.5	68.0	54.8	58.9
N	12	12	12	12	11		N	11	11	11	11	10